|
10 Companies |
|
11 Products |
|
11 Products |
|
25 Mechanisms of Action |
|
0 Trials |
|
30 News |
|
- Trial completion: High-dose ICE With Amifostine (clinicaltrials.gov) - Jan 23, 2017
P2, N=24, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed
- sirolimus / Generic mfg.
Trial completion, Enrollment change: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Oct 4, 2016
P1, N=18, Completed, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=30 --> 18
- ||| Biomarker, Trial completion, Trial primary completion date: Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor (clinicaltrials.gov) - May 20, 2016
P=N/A, N=185, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | N=30 --> 18 Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- || Trial primary completion date, Surgery: AREN0321: Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors (clinicaltrials.gov) - Apr 15, 2016
P2, N=294, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Trial primary completion date: Sep 2014 --> Dec 2015
- sirolimus / Generic mfg.
Enrollment change: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Nov 15, 2015
P1, N=30, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Sep 2014 --> Dec 2015 N=18 --> 30
- albumin-bound paclitaxel / Generic mfg.
Biomarker, Enrollment change, Metastases: Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=0, Withdrawn, Sponsor: Eastern Cooperative Oncology Group
N=18 --> 30 N=129 --> 0
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial completion, Enrollment change, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - May 26, 2015
P1b, N=78, Completed, Sponsor: National Cancer Institute (NCI)
N=129 --> 0 Active, not recruiting --> Completed | N=120 --> 78
- sirolimus / Generic mfg.
Enrollment closed, Enrollment change: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Apr 29, 2015
P1, N=18, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed | N=120 --> 78 Recruiting --> Active, not recruiting | N=30 --> 18
- |||| Trial completion, Trial primary completion date, Surgery: AREN0321: Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors (clinicaltrials.gov) - Feb 5, 2015
P2, N=294, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting | N=30 --> 18 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Sep 2014
- Trial completion, Enrollment change, Trial primary completion date, Metastases: Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=329, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Sep 2014 Active, not recruiting --> Completed | N=450 --> 329 | Trial primary completion date: May 2013 --> Sep 2013
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial primary completion date, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Nov 7, 2014
P1b, N=120, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=450 --> 329 | Trial primary completion date: May 2013 --> Sep 2013 Trial primary completion date: Nov 2014 --> Apr 2015
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Enrollment closed, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Oct 10, 2014
P1b, N=120, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2014 --> Apr 2015 Recruiting --> Active, not recruiting
- | Granocyte (lenograstim) / Roche
Trial completion, Surgery: EORTC-STBSG 62931: Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 8, 2014
P3, N=350, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- sirolimus / Generic mfg.
Trial primary completion date: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Aug 7, 2014
P1, N=30, Recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Trial primary completion date: Sep 2014 --> Sep 2016
- ||||| Trial initiation date, Surgery: Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors (clinicaltrials.gov) - Jul 27, 2014
P3, N=203, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Sep 2014 --> Sep 2016 Initiation date: May 2002 --> Jan 1996
- | Trial completion, Surgery: Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors (clinicaltrials.gov) - Jul 23, 2014
P3, N=203, Completed, Sponsor: Children's Oncology Group
Initiation date: May 2002 --> Jan 1996 No longer recruiting --> Completed
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial primary completion date, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Jul 21, 2014
P1b, N=120, Recruiting, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Trial primary completion date: Aug 2014 --> Nov 2014
- | thalidomide / Generic mfg., docetaxel / Generic mfg.
Trial completion, Metastases: Thalidomide and Docetaxel in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=26, Completed, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Aug 2014 --> Nov 2014 Active, not recruiting --> Completed
- | Genasense (oblimersen) / Genta
Trial completion, Metastases: Chemotherapy in Treating Patients With Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=57, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Enrollment closed, Surgery: AREN0321: Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors (clinicaltrials.gov) - Feb 11, 2014
P2, N=291, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial termination: Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer (clinicaltrials.gov) - Jan 30, 2014
P3, N=22, Terminated, Sponsor: University of South Florida
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; The study was terminated due to slow accrual.
- Enrollment change: Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer (clinicaltrials.gov) - Jan 30, 2014
P3, N=22, Terminated, Sponsor: University of South Florida
Active, not recruiting --> Terminated; The study was terminated due to slow accrual. N=178 --> 22
- sirolimus / Generic mfg.
Enrollment change: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Oct 10, 2013
P1, N=30, Recruiting, Sponsor: Roswell Park Cancer Institute
N=178 --> 22 N=20 --> 30
- TXA-127 / Constant Therap
Trial completion, Surgery, Metastases: Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jul 28, 2013
P2, N=20, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
N=20 --> 30 Active, not recruiting --> Completed
- || Biomarker, Enrollment change: Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor (clinicaltrials.gov) - Jul 7, 2013
P=N/A, N=185, Recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed N=100 --> 185
- ||| Biomarker, Enrollment open: Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor (clinicaltrials.gov) - Jul 7, 2013
P=N/A, N=185, Recruiting, Sponsor: Children's Oncology Group
N=100 --> 185 Not yet recruiting --> Recruiting
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Enrollment open, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Mar 3, 2013
P1b, N=120, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Surgery: SWOG-EORTC-62933: Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 9, 2012
P3, N=340, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- sirolimus / Generic mfg.
Enrollment open: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Mar 25, 2012
P1, N=30, Recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- TXA-127 / Constant Therap
New P2 trial, Surgery, Metastases: Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery (clinicaltrials.gov) - Mar 12, 2012
P2, N=20, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
- sirolimus / Generic mfg.
New P1 trial: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Jan 30, 2012
P1, N=30, Recruiting, Sponsor: Roswell Park Cancer Institute